Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival.

Yasuno M, Uetake H, Ishiguro M, Mizunuma N, Komori T, Miyata G, Shiomi A, Kagimura T, Sugihara K.

Int J Clin Oncol. 2019 May;24(5):516-525. doi: 10.1007/s10147-018-01393-8. Epub 2019 Jan 5.

PMID:
30612267
2.

A multicenter phase II trial of mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808).

Uetake H, Yasuno M, Ishiguro M, Kameoka S, Shimada Y, Takahashi K, Watanabe T, Muro K, Baba H, Yamamoto J, Mizunuma N, Tamagawa H, Mochizuki I, Kinugasa Y, Kikuchi T, Sugihara K.

Ann Surg Oncol. 2015 Mar;22(3):908-15. doi: 10.1245/s10434-014-4094-7. Epub 2014 Dec 3.

PMID:
25465375
3.

Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study).

Hatano E, Okuno M, Nakamura K, Ishii T, Seo S, Taura K, Yasuchika K, Yazawa T, Zaima M, Kanazawa A, Terajima H, Kaihara S, Adachi Y, Inoue N, Furumoto K, Manaka D, Tokka A, Furuyama H, Doi K, Hirose T, Horimatsu T, Hasegawa S, Matsumoto S, Sakai Y, Uemoto S.

J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):634-45. doi: 10.1002/jhbp.254. Epub 2015 Apr 29.

PMID:
25926024
4.

Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.

Nagayama S, Hasegawa S, Hida K, Kawada K, Hatano E, Nakamura K, Seo S, Taura K, Yasuchika K, Matsuo T, Zaima M, Kanazawa A, Terajima H, Tada M, Adachi Y, Nishitai R, Manaka D, Yoshimura T, Doi K, Horimatsu T, Mitsuyoshi A, Yoshimura K, Niimi M, Matsumoto S, Sakai Y, Uemoto S.

Int J Clin Oncol. 2017 Apr;22(2):316-323. doi: 10.1007/s10147-016-1050-5. Epub 2016 Oct 17.

PMID:
27752787
5.

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.

Gruenberger T, Bridgewater J, Chau I, García Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R.

Ann Oncol. 2015 Apr;26(4):702-8. doi: 10.1093/annonc/mdu580. Epub 2014 Dec 23.

PMID:
25538173
6.

Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.

Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J.

J Clin Oncol. 2013 Jun 1;31(16):1931-8. doi: 10.1200/JCO.2012.44.8308. Epub 2013 Apr 8.

PMID:
23569301
7.

Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study.

Takahashi T, Shibata Y, Tojima Y, Tsuboi K, Sakamoto E, Kunieda K, Matsuoka H, Suzumura K, Sato M, Naganuma T, Sakamoto J, Morita S, Kondo K.

Int J Clin Oncol. 2013 Apr;18(2):335-42. doi: 10.1007/s10147-012-0382-z. Epub 2012 Mar 2.

PMID:
22383023
8.

Preoperative Chemotherapy with Bevacizumab Extends Disease-free Survival After Resection of Liver Metastases from Colorectal Cancer.

Umehara M, Umehara Y, Takahashi K, Murata A, Nishikawa S, Tokura T, Matsuzaka M, Tanaka R, Morita T.

Anticancer Res. 2016 Apr;36(4):1949-54.

PMID:
27069185
9.

Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.

DʼAngelica MI, Correa-Gallego C, Paty PB, Cercek A, Gewirtz AN, Chou JF, Capanu M, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N.

Ann Surg. 2015 Feb;261(2):353-60. doi: 10.1097/SLA.0000000000000614.

10.

Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV.

Lévi FA, Boige V, Hebbar M, Smith D, Lepère C, Focan C, Karaboué A, Guimbaud R, Carvalho C, Tumolo S, Innominato P, Ajavon Y, Truant S, Castaing D, De Baere T, Kunstlinger F, Bouchahda M, Afshar M, Rougier P, Adam R, Ducreux M; Association Internationale pour Recherche sur Temps Biologique et Chronothérapie (ARTBC International).

Ann Oncol. 2016 Feb;27(2):267-74. doi: 10.1093/annonc/mdv548. Epub 2015 Nov 16.

PMID:
26578731
11.

[Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases].

Kaibori M, Iwamoto S, Ishizaki M, Matsui K, Saito T, Yoshioka K, Kwon AH.

Gan To Kagaku Ryoho. 2009 Dec;36(13):2579-82. Japanese.

PMID:
20009458
12.

Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab.

Sasaki K, Margonis GA, Andreatos N, Wilson A, Weiss M, Wolfgang C, Sergentanis TN, Polychronidis G, He J, Pawlik TM.

Br J Surg. 2017 Jun;104(7):926-935. doi: 10.1002/bjs.10510. Epub 2017 Mar 7.

PMID:
28266705
13.
14.

Long-Term Outcomes of Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastases.

Maeda Y, Shinohara T, Nagatsu A, Futakawa N, Hamada T.

Ann Surg Oncol. 2016 Feb;23 Suppl 2:S242-8. doi: 10.1245/s10434-015-4460-0. Epub 2015 Mar 7.

PMID:
25749931
15.

A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis.

Kim KH, Shin SJ, Cho MS, Ahn JB, Jung M, Kim TI, Park YS, Kim H, Kim NK, Koom WS.

Radiother Oncol. 2016 Feb;118(2):369-74. doi: 10.1016/j.radonc.2015.11.029. Epub 2015 Dec 17.

PMID:
26705682
16.

Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.

Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H.

Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8.

17.

A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.

Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, Letoublon C, Guimbaud R, Francois E, Ducreux M, Desseigne F, Fabre JM, Assenat E.

Ann Surg Oncol. 2013 Dec;20(13):4289-97. doi: 10.1245/s10434-013-3217-x. Epub 2013 Aug 17.

PMID:
23955585
18.

Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival.

Beppu T, Miyamoto Y, Sakamoto Y, Imai K, Nitta H, Hayashi H, Chikamoto A, Watanabe M, Ishiko T, Baba H.

Ann Surg Oncol. 2014 Jun;21 Suppl 3:S405-13. doi: 10.1245/s10434-014-3577-x. Epub 2014 Feb 26.

PMID:
24570379
19.

Portal vein embolization does not affect the long-term survival and risk of cancer recurrence among colorectal liver metastases patients: A prospective cohort study.

Collin Y, Paré A, Belblidia A, Létourneau R, Plasse M, Dagenais M, Turcotte S, Martel G, Roy A, Lapointe R, Vandenbroucke-Menu F.

Int J Surg. 2019 Jan;61:42-47. doi: 10.1016/j.ijsu.2018.11.029. Epub 2018 Dec 8.

PMID:
30537548
20.

Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).

Beppu T, Emi Y, Tokunaga S, Oki E, Shirabe K, Ueno S, Kuramoto M, Kabashima A, Takahashi I, Samura H, Eguchi S, Akagi Y, Natsugoe S, Ogata Y, Kakeji Y, Baba H, Maehara Y; Kyushu Study group of Clinical Cancer (KSCC).

Anticancer Res. 2014 Nov;34(11):6655-62.

PMID:
25368271

Supplemental Content

Support Center